Literature DB >> 30187332

Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.

Douglas S Swords1, Samual R Francis2, Shane Lloyd2, Ignacio Garrido-Laguna3, Sean J Mulvihill4, Joshua D Gruhl2, Miles C Christensen2, Gregory J Stoddard5, Matthew A Firpo4, Courtney L Scaife4.   

Abstract

BACKGROUND: Single-center studies in pancreatic adenocarcinoma have suggested that preoperative chemotherapy (PCT) is associated with higher lymph node ratio (LNR) than preoperative chemoradiation (PCRT). The association of postoperative chemotherapy with overall survival (OS) in patients treated with PCT and PCRT remains unclear. Our objectives were to investigate whether (1) PCT is associated with higher LNR than PCRT and (2) postoperative chemotherapy is associated with longer OS after PCT and PCRT in LNR-stratified cohorts.
METHODS: A retrospective cohort study was performed of patients with pancreatic adenocarcinoma treated with PCT or PCRT followed by resection between 2006 and 2014 in the National Cancer Database. Temporal trends were evaluated with Cuzick's test. OS was evaluated with multivariable Cox regression and inverse probability weighted (IPW) Cox regression.
RESULTS: Of 4187 patients, 1993 (47.6%) received PCT. PCT rates were stable at approximately 30% in 2006-2010 (p = 0.33) but increased to 64.9% by 2014 (p < 0.001). Node positivity rates were higher after PCT than PCRT (62.7 vs. 41.8%, P < 0.001) and mean LNR was higher (0.10 [95% CI 0.096, 0.11] vs. 0.058 [95% CI 0.052, 0.063], P < 0.001). Postoperative chemotherapy was associated with longer OS in patients with LNR 0.01-0.149 after PCT by univariate analysis (median OS 34.5 vs. 26.5 months, P = 0.002), multivariable Cox regression (HR 0.64, 95% CI 0.48, 0.84), and IPW Cox regression (HR 0.72, 95% CI 0.55, 0.94). Postoperative chemotherapy was not associated with longer OS for patients who were node-negative or who had LNR ≥ 0.15 after PCT or for any patient subgroups after PCRT.
CONCLUSIONS: PCT is associated with a higher LNR and higher rates of node positivity than PCRT. Postoperative chemotherapy is associated with longer OS than observation in patients with a LNR of 0.01-0.149 after PCT.

Entities:  

Keywords:  Adjuvant; Chemoradiation; Chemotherapy; LNR; Lymph node ratio; Neoadjuvant; Nodal status; PDAC; Pancreatic adenocarcinoma; Postoperative; Preoperative

Year:  2018        PMID: 30187332     DOI: 10.1007/s11605-018-3953-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  45 in total

1.  Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression.

Authors:  Mirjam J Knol; Saskia Le Cessie; Ale Algra; Jan P Vandenbroucke; Rolf H H Groenwold
Journal:  CMAJ       Date:  2011-12-12       Impact factor: 8.262

2.  Estimating causal effects from epidemiological data.

Authors:  Miguel A Hernán; James M Robins
Journal:  J Epidemiol Community Health       Date:  2006-07       Impact factor: 3.710

3.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

4.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 5.  Landmark analysis at the 25-year landmark point.

Authors:  Urania Dafni
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-05

6.  Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.

Authors:  Jeannelyn S Estrella; Asif Rashid; Jason B Fleming; Matthew H Katz; Jeffrey E Lee; Robert A Wolf; Gauri R Varadhachary; Peter W T Pisters; Eddie K Abdalla; Jean-Nicolas Vauthey; Hua Wang; Henry F Gomez; Douglas B Evans; James L Abbruzzese; Huamin Wang
Journal:  Cancer       Date:  2011-07-06       Impact factor: 6.860

7.  Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.

Authors:  Avo Artinyan; Daniel A Anaya; Shaun McKenzie; Joshua D I Ellenhorn; Joseph Kim
Journal:  Cancer       Date:  2010-11-18       Impact factor: 6.860

8.  Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.

Authors:  Stefan Heinrich; Markus Schäfer; Achim Weber; Thomas F Hany; Ujwal Bhure; Bernhard C Pestalozzi; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

9.  Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.

Authors:  Stefan Heinrich; Bernhard C Pestalozzi; Markus Schäfer; Achim Weber; Peter Bauerfeind; Alexander Knuth; Pierre-Alain Clavien
Journal:  J Clin Oncol       Date:  2008-05-20       Impact factor: 44.544

10.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

View more
  1 in total

1.  Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.

Authors:  Sivesh K Kamarajah; Steven A White; Samer A Naffouje; George I Salti; Fadi Dahdaleh
Journal:  Ann Surg Oncol       Date:  2021-03-30       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.